332 results for "Hashimoto, Kenji"
Showing 1–20 · 0.47 seconds · RSS
-
Journal Article Full text
The R-Stereoisomer of Ketamine as an Alternative for Ketamine for Treatment-resistant Major Depression
-
Journal Article Full text
A BDNF Val66Met Polymorphism and Ketamine-induced Rapid Antidepressant Action
-
Journal Article Full text
Glycine Transport Inhibitors for the Treatment of Schizophrenia
Multiple lines of evidence indicate that hypofunction of glutamatergic neurotransmission via N-methyl-D-aspartate (NMDA) receptors might be implicated in the pathophysiology of schizophrenia, suggesting that increasing NMDA receptor function via pharmacological manipulation could provide a new…
-
Journal Article Full text
Role of Soluble Epoxide Hydrolase in Metabolism of PUFAs in Psychiatric and Neurological Disorders
Inflammation plays a key role in the pathogenesis of a number of psychiatric and neurological disorders. Soluble epoxide hydrolases (sEH), enzymes present in all living organisms, metabolize epoxy fatty acids (EpFAs) to corresponding 1,2-diols by the addition of a molecule of water. Accumulating…
-
Journal Article Full text
Essential Role of Keap1-Nrf2 Signaling in Mood Disorders: Overview and Future Perspective
Depression is one of the most common mood disorders with a high rate of relapse. Accumulating evidence suggests that the transcription factor Kelch-like erythroid cell-derived protein with CNC homology (ECH)-associated protein 1 (Keap1)-Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) system…
-
Journal Article Full text
Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational Biomarker
Accumulating evidence suggests that the α7 subtype of nicotinic acetylcholine receptors (nAChRs) plays a key role in inflammatory processes, thought to be involved in the pathophysiology of neuropsychiatric diseases, such as schizophrenia and Alzheimer’s disease. Preclinical and clinical studies…
-
Journal Article Full text
Inflammatory Biomarkers as Differential Predictors of Antidepressant Response
Although antidepressants are generally effective in the treatment of major depressive disorder (MDD), it can still take weeks before patients feel the full antidepressant effects. Despite the efficacy of standard treatments, approximately two-thirds of patients with MDD fail to respond to…
-
Journal Article Full text
Are NMDA and opioid receptors involved in the antidepressant actions of ketamine?
-
Journal Article Full text
Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective
Major depressive disorder (MDD) is one of the most disabling psychiatric disorders. Approximately one‐third of the patients with MDD are treatment resistant to the current antidepressants. There is also a significant therapeutic time lag of weeks to months. Furthermore, depression in patients with…
-
Journal Article Full text
Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor
The novel coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The escalating number of SARS-CoV-2-infected individuals has conferred the viral spread with the status of global pandemic. However, there are no prophylactic or therapeutic…
-
Journal Article Full text
Emerging role of the host microbiome in neuropsychiatric disorders: overview and future directions
The human body harbors a diverse ecosystem of microorganisms, including bacteria, viruses, and fungi, collectively known as the microbiota. Current research is increasingly focusing on the potential association between the microbiota and various neuropsychiatric disorders. The microbiota resides in…
-
Journal Article Full text
Evaluating the safety of orexin receptor antagonists on reproductive health and sexual function
-
Journal Article Full text
Viewpoints Sigma-1 receptor agonist fluvoxamine for multiple sclerosis
Accumulating evidence suggests that the Epstein-Barr virus (EBV) plays a key role in the development of multiple sclerosis (MS). Additionally, depressive symptoms often precede the onset of MS. Given the role of the XBP1-sigma-1 receptor complex in the endoplasmic reticulum during EBV reactivation…
-
Journal Article Full text
Detrimental effects of COVID-19 in the brain and therapeutic options for long COVID: The role of Epstein–Barr virus and the gut–brain axis
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has resulted in a serious public health burden worldwide. In addition to respiratory, heart, and gastrointestinal symptoms, patients infected with SARS-CoV-2 experience…
-
Journal Article Full text
CD137 as an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug Development
SIMPLE SUMMARY: CD137 is an interesting immuno-oncology target. The recent advances in CD137 targeting technologies to mitigate toxicity while maintaining potency have made this space even more attractive. In this article, our current understanding of CD137 biology is reviewed along with data from…